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Malignant mesothelioma (MpM) is an aggressive, invariably fatal tumour that is causally
linked with asbestos exposure. The disease primarily results from loss of tumour suppressor
gene function and there are no ‘druggable’ driver oncogenes associated with MpM. To
identify opportunities for management of this disease we have carried out polysome profiling
to define the MpM translatome. We show that in MpM there is a selective increase in the
translation of mRNAs encoding proteins required for ribosome assembly and mitochondrial
biogenesis. This results in an enhanced rate of mRNA translation, abnormal mitochondrial
morphology and oxygen consumption, and a reprogramming of metabolic outputs. These
alterations delimit the cellular capacity for protein biosynthesis, accelerate growth and drive
disease progression. Importantly, we show that inhibition of mRNA translation, particularly
through combined pharmacological targeting of mTORC1 and 2, reverses these changes and
inhibits malignant cell growth in vitro and in ex-vivo tumour tissue from patients with end-
stage disease. Critically, we show that these pharmacological interventions prolong survival
in animal models of asbestos-induced mesothelioma, providing the basis for a targeted, viable
therapeutic option for patients with this incurable disease.
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Malignant pleural Mesothelioma (MpM) is an aggressive,near-universally fatal malignancy of the pleura that isalmost exclusively associated with exposure to
asbestos1–4. There is no effective treatment and, after a long
latency period following initial exposure, it progresses rapidly5,6.
At present, the standard of care for MpM is chemotherapy based
on a combination of pemetrexed and cisplatin or radical surgery6,
both of which are at best modestly effective at prolonging the life
of patients, although emerging therapies, which target immune
system checkpoints may be of value in the future7,8.
The mechanisms of carcinogenesis driven by asbestos exposure
are poorly understood and our limited knowledge of the mole-
cular changes associated with MpM severely hampers therapeutic
development5. Extensive genomic analyses have been performed
on MpM tumours9–12 and for the most part, these were found to
be enriched for mutations and/or other genetic alterations (e.g.,
splicing changes and gene deletions) that result in a decrease in
tumour suppressor gene function rather than the acquisition of
mutations that activate proto-oncogenes10,11. For example, sev-
eral human studies have shown that p16INK4a, p14ARF, NF2 and
BAP1 are altered in MpM, with p16INK4a and p14ARF deleted in
80–90% of cases11,13–15 and BAP116 and NF214, which are
mutated/deleted in over 20% of cases11,17. The central role of
these genes in the development of MpM is corroborated by ani-
mal studies showing that their deletion/inactivation results in the
greatly accelerated development of aggressive mesotheliomas in
asbestos-exposed animals17–20. Moreover, mouse studies have
also shown that hypermethylation of p16/Ink4a and p19/Arf in
asbestos-induced inflammatory lesions precedes mesothelioma,
resulting in silencing of cdkn2A (Ink4a/Arf) and loss of p16 and
p19 protein20.
In addition to mutations and deletions in DNA that initiate
tumorigenesis, it is well accepted that dysregulated cytoplasmic
control of gene expression at the level of mRNA translation has a
major role in both cancer development and progression21,22. In
general, global translation initiation rates are regulated by ternary
complex recycling and eukaryotic initiation factor 4F complex
(eIF4F) assembly21,23. The latter complex is comprised of eIF4E
(the cap-binding protein), eIF4G (a scaffold protein) and eIF4A
(a DEAD-box helicase). Two associated proteins, eIF4B and the
functionally related eIF4H, anchor the complex to the mRNA and
increase eIF4A helicase activity. Dysregulation of eIF4F complex
members drives tumorigenesis via increased synthesis of proteins
that are normally poorly translated, particularly those encoding
growth factors and oncogenes24–26. In addition, aberrant signal-
ling via the PI3K-mammalian/mechanistic target of rapamycin
(mTOR) axis activates protein synthesis, through increased
phosphorylation of the components that regulate eIF4F complex
assembly (e.g., 4EBPs and PDCD4) and ribosomes24,27 and
interestingly, a number of studies have identified this pathway as
being upregulated in MpM20,28–30. There are data to suggest that
the product of NF2, Merlin, inhibits mTORC1 signalling, pro-
viding a rationale as to why this pathway is upregulated in NF2-
deficient MpM, although the molecular mechanisms that link
these two events have not been elucidated31.
Here, we show that in MpM there is a selective increase in the
translation of mRNAs encoding proteins required for ribosome
assembly and mitochondrial biogenesis, and this results in an
enhanced global rate of mRNA translation, abnormal mito-
chondrial morphology and oxygen consumption, and repro-
gramming of metabolic outputs. However, inhibition of mRNA
translation by pharmacological targeting of mTORC1 and 2,
reverses these changes both in vitro and in ex vivo patient tumour
tissue. Moreover, such mTORC1 and 2 inhibition extends sur-
vival in animal models of asbestos-induced mesothelioma and
taken together, our data suggest that targeting mRNA translation
could provide a viable, alternative treatment route for this
incurable disease.
Results
Aberrant mRNA translation leads to upregulation in the
synthesis of mitochondrial proteins and components of the
translation apparatus. In previous studies, we established a series
of patient-derived primary mesothelioma cell lines that have
characteristics that are representative of MpM tumours with loss
of NF2 (merlin) and CDKN2A32. Importantly, these primary cell
lines also show a degree of molecular diversity, thus capturing the
disease heterogeneity in a patient cohort32. MpM has no known
oncogenic drivers, therefore, we used these cells to determine
changes to the translatome; cell lines used included Meso 3 T, 7 T,
8 T, 9 T, 12 T, 14 T and 17 T as described32, in addition to 13 T
which was generated at the same time, and has the same MpM
characteristics. Peritoneal mesothelial cells either from a single
healthy individual (NM) or a pool of healthy donors (NMS) were
used as controls.
The majority of tumours display increased protein synthesis
rates22 and consistent with these findings, both methionine
incorporation assays (Fig. 1a) and puromycin labelling (Supple-
mentary Fig. 1A) showed that MpM-derived tumour cells have
greatly elevated global levels of mRNA translation. Moreover,
sucrose density gradient analysis (Supplementary Fig. 1B), which
allows the separation of actively translating ribosomes (polysomes)
from subpolysomal particles, shows an increase in the association
of mRNAs with the polysome in MpM cells (Fig. 1b, Supplemen-
tary Fig. 1B). In addition to a global upregulation of protein
synthesis, the data suggest that most cancers additionally have
increased translation of specific mRNAs22. To identify the mRNAs
that were selectively translated in MpM, polysome profiling was
performed. This technique allows the identification of candidate
mRNAs whose translational behaviour differs significantly from
the translation pattern observed in the control cells. This was
carried out using cytoplasmic extracts prepared from 8 MpM-
derived primary cell lines (Meso 3 T, 7 T, 8 T, 9 T, 12 T, 13 T, 14 T
and 17 T) and two controls of primary mesothelial cells obtained
from a healthy individual (NM) or a pool of healthy donors
(NMS). The data showed that the translatome of MpM-derived
primary cell lines clustered together, distinct from the controls
(Fig. 1c, Supplementary Fig. 1C) with a significant number of
mRNAs showing alterations in the degree of polysomal associa-
tion (Fig. 1d, Supplementary data 1; the number of genes
significantly upregulated was 1665, whereas 282 were down-
regulated) as confirmed by qPCR (Supplementary Fig. 2A, B). The
transcripts that were significantly upregulated were classified
based on their biological function and the top upregulated GO
terms included mitochondria, electron transport chain compo-
nents, ribosomal proteins and canonical translational machinery
(Table 1, Supplementary data 2). Importantly, these GO terms are
distinct from those obtained when transcriptional profiling was
carried out on these lines32. The mRNAs that were more
polysomally associated had shorter and unstructured 5′-UTRs
(Table 2) compared with the downregulated. Although some of
the mRNAs found to be translationally upregulated contained a
terminal oligopyrimidine track (TOP) motif, there was not a
significant enrichment in this category of mRNAs (Table 2). We
did not find any enrichment of internal ribosome entry sites33,
however, for the mRNAs encoding mitochondrial proteins, there
was an enrichment of the TISU sequence in the 5′-UTR34.
Western blot analysis to confirm changes in expression of
proteins that form part of the ribosomes (Fig. 1e and
Supplementary Fig. 2C) identified large increases in the expression
of selected ribosomal proteins in both the small and large subunit
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proteins, ranging from a threefold change in rpS6 to over 80-fold
for rpL24 (Fig. 1e). We also identified increased expression of
canonical and non-canonical RNA binding proteins that control
translation, e.g., increased expression of eIF4A1, DAP5 (which is
encoded by eIF4G2) and DDX3 (Fig. 1e and Supplementary
Fig. 2D). We additionally identified increases in eIF6 and eIF4E, in
agreement with previous studies35,36 (Fig. 1e and Supplementary
Fig. 2D). Proteins required for mitochondrial oxidative phosphor-
ylation, e.g., mitochondrial ATP synthase (ATP5A) and
ubiquinol-cytochrome c reductase complex (UQCR2) and the
TCA cycle, including succinate dehydrogenase (SDH) (Fig. 1e and
Supplementary Fig. 2E), were also confirmed as upregulated by
western blot analysis. As controls, we used eIF4G1 or eIF4A2 that
showed no change agreement with the array data and neogenin a
protein involved in neurogenesis (Supplementary Fig. 2B, F);
which was downregulated, in agreement with the profiling data.
We then asked whether there was a correlation between
tumour cell growth and the activation of mRNA translation and
expression of mitochondrial proteins. This was achieved by
generating a tissue microarray (TMA), comprised of 272 archival
formalin-fixed surgical tumour samples from individuals with
mesothelioma (Supplementary Fig. 3A). These data showed, in
agreement with previous studies, that epithelioid histology has a
better outcome than sarcomatoid tumours (Supplementary
Fig. 3B). The TMAs were probed with antibodies against Ki67


























































































































10  (p val)














































































































































































































































NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-25173-7 ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:4920 | https://doi.org/10.1038/s41467-021-25173-7 |www.nature.com/naturecommunications 3
as upregulated in the primary MpM-derived cell lines, including
eIF4A, rpS6, ATP5A and SDH (Fig. 1e and Fig. 2a). Quantitative
protein expression data were obtained from images using
Visiopharm® software and a tumour cell cytoplasm-specific H-
score was obtained using duplex staining for cytokeratin
expression. The automated method was validated against manual
scoring (Supplementary Fig. 3C, D). As expected, the data show
that patients with a high expression of the proliferation marker
Ki67 have a significantly worse overall survival rate (Fig. 2b).
Importantly, there were significant positive associations between
expression of Ki67 and P rpS6, SDH, eIF4A and ATP5A,
consistent with a link between or co-regulation of the processes of
protein synthesis, mitochondrial function and enhanced cell
growth in MpM tumours (Fig. 2c–f).
Mitochondria in MpM show distinct morphological changes.
Given the unexpected selective upregulated synthesis of nuclear-
encoded proteins with mitochondrial functions, we also assessed
whether there were changes in mitochondrial morphology, func-
tion and metabolism. Electron microscopy revealed significant
ultrastructural alterations to mitochondria in MpM-derived cell
lines (Fig. 3a), with rounded and enlarged 2D cross-sectional
appearances (Fig. 3b and Supplementary Fig. 4). Mitochondria
form a dynamic network, changes in which are associated with a
range of diseases37. To assess alterations in the mitochondrial
network, confocal microscopy was used (Fig. 3c). In control cells,
the mitochondria form an elongated network, whereas in MpM
cells mitochondria were fragmented (Figs. 3c, d). Mitochondrial
dynamics are controlled by mitochondrial fission process 1
(MTFP1), which couples pro-fission phosphorylation (Ser616)
and mitochondrial recruitment of dynamin-related protein 1
(DRP1), whereas fusion is regulated by mitofusion 1 and 2. Sig-
nificantly increased expression of the pro-fission protein MTFP1
and enhanced phosphorylation of DRP1 were detected in MpM
cells (Fig. 3e, f), which were consistent with the changes in
Fig. 1 Aberrant translational regulation increases the synthesis of ribosomal proteins, protein synthesis machinery and mitochondrial components.
a To assess protein synthesis rates, healthy mesothelial cells (NM) and primary MpM-derived cell lines were incubated with 35 S methionine and the rate
of incorporation over a 30min period was assessed. Error bars represent standard deviation and the measure of the centre of the error bars is the mean
(n= 3, where n= number of biological repeats of 35 S methionine incorporation experiment) and significance was assessed using two-sided unpaired
student’s t test with multiple comparisons, p values are shown on the bar graphs. b Polysome profiles of either healthy mesothelial cells (NM and NMS) or
MpM-derived cell lines were obtained (n= 3, representative profile shown in Supplementary Fig. 1B, where n= number of biological repeats of the
polysome profile experiment) and the area attributed to the subpolysomes (blue; subpolysomes fraction contains the 40 S, 60 S SUs and 80 S ribosomes
and are generally not associated with translating mRNAs) or polysomes (red, polysomes are associated with translating mRNAs) calculated. Error bars
represent standard deviation and the measure of the centre of the error bars is the mean (n= 3). Significance was assessed using a two-sided unpaired
student’s t test with multiple comparisons, p values are shown on the bar graphs. c Polysome profiling was carried out using eight primary tumour cell lines
and two controls with three biological repeats of each tumour cell or control cells used. Translation efficiency pattern and hierarchical clustering of control
(NM–cells from a single donor and NMS–pool from four donors) and eight primary mesothelioma cell lines (n= 3 in each case). The heatmap displays the
polysomal association of the most variable transcripts across the samples (fold change >2 compared with NM control). The legend bar shows the colour
code for the normalised log intensity values. The hierarchical clustering shows the measure of the Pearson Correlation distance. d Volcano plot
representing in red the mRNAs with the significant polysomal association and in blue a minority of downregulated transcripts. Polysome profiling array was
analysed by RankProd, which generates two lists: the UP list (dark grey) contains every gene, their FC and their probability of being truly upregulated, and
the DOWN list (light grey), with every gene, their FC and their probability of being truly downregulated. Each gene was included twice. Specifically, one arm
of the plot includes all the genes with their probability of being UP, and the other arm of the plot includes all the genes and their probability of being DOWN
regulated. e Densitometric analysis of the western blots in Supplementary Figs. 2C–E. Protein levels in MpM-derived cell lines are compared with NMS
control cells. Error bars represent standard deviation and the measure of the centre of the error bars is the mean (n= 8 independent biological repeats) and
significance was assessed using unpaired two-sided student’s t test adjusted for multiple comparisons, p values are shown on the bar graphs. Ribosomal
factors are shown in the red bars, initiation factors in blue and mitochondrial proteins in green.
Table 1 Table showing the top 10 enriched clusters of highly translated mRNAs in MpM-derived cell lines.
No. GO term Description Odds ratio P value
1 GO:0005739 Mitochondrion 2.21 2.60E-13
2 GO:0022904 Respiratory electron transport chain 5.73 4.68E-10
3 GO:0016070 RNA metabolic process 3.52 2.93E-08
4 GO:0003735 Structural constituent of ribosome 4.27 4.68E-07
5 GO:0006412 Translation 3.45 1.05E-06
6 GO:0010467 Gene expression 2.36 3.56E-06
7 GO:0005743 Mitochondrial inner membrane 2.94 5.99E-03
8 GO:0016071 mRNA metabolic process 3.27 5.76E-02
9 GO:0016032 Viral reproduction 2.77 9.52E-02
10 GO:0000216 M/G1 transition of mitotic cell cycle 4.87 1.77E-01
Gene Ontology terms (Biological Processes) were used for the analysis. The most enriched clusters were related to mitochondria and protein synthesis.
Table 2 Structural features of the mRNAs that are most
upregulated.
Description P value
shorter 5′-UTR t test *** 2.805E-08
higher 5′-UTR MFE t test *** 1.558E-11
fewer uORF χ2 *** 1.096E-07
TISU elements χ2 *** 6.074E-06
TOP/TOP like χ2 ns
AU-rich elements χ2 ns
These included upstream open-reading frame (uORF)= 833; terminal oligopyrimidine tract
TOP/TOP-like= 126; AU-rich elements= 297; translation initiator of short 5′-UTR, TISU= 28
MFE=minimum-free energy.
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Fig. 2 Protein synthesis and mitochondrial protein expression correlate with poor survival in patient-derived material. a Representative section of
tissue microarray (TMA) probed with antibodies against phospho-Ser240/244 rpS6 (magenta) and SDH (magenta). Tumour areas within the TMA cores
were identified by cytokeratin staining (yellow). Visiopharm® software was used to quantify the magenta staining in the tumour area. b Kaplan–Meier plot,
showing Ki67 staining is a strong predictor of survival. The 272 patients included in the TMAs, were split into two equally sized groups according to Ki67
H-score. A log-rank test was performed to determine the significance of differences in survival (*p= 0.025). c Scatter plot of the H-scores of rpS6
phosphorylation (mTOR activity) and Ki67 expression in mesothelioma TMAs. Linear regression analysis was performed by Spearman’s rank correlation,
the coefficient was 0.274. The linear regression fit is depicted with a blue line. The grey band shown is the 95% confidence interval. d Scatter plot of the
H-scores of eIF4A1 expression and Ki67 expression in mesothelioma TMAs. Linear regression analysis was performed by Spearman’s rank correlation, the
coefficient was 0.26. The linear regression fit is depicted with a blue line. The grey band shown is the 95% confidence interval. e Scatter plot of the
H-scores of mitochondrial ATP5A expression and Ki67 expression in mesothelioma TMAs. Linear regression analysis was performed by Spearman’s rank
correlation, the coefficient was 0.182. The linear regression fit is depicted with a blue line. The grey band shown is the 95% confidence interval. f Scatter
plot of the H-scores of mitochondrial SDH expression and Ki67 expression in mesothelioma TMAs. Linear regression analysis was performed by
Spearman’s rank correlation, the coefficient was 0.116. The linear regression fit is depicted with a blue line. The grey band shown is the 95% confidence
interval.
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mitochondrial shape observed in confocal and electron
microscopy.
Metabolic changes in aberrant MpM-derived mitochondria
provide energy and metabolites for tumour cell growth. To
assess whether the differences in mitochondrial shape and net-
work in MpM are associated with alterations in oxidative phos-
phorylation, oxygen consumption rate (OCR) was measured
(Fig. 4a). The data show that basal (Fig. 4b) and maximum OCR
(Fig. 4c) were raised in MpM-derived cell lines relative to the
control, suggesting that upregulation of oxidative phosphoryla-
tion provides energy to drive the synthesis of proteins and
organelles required for the high rate of tumour cell proliferation.
We then asked whether there were changes in the steady-state
levels of metabolites involved in major bioenergetic pathways
required to drive cell growth in MpM. Cells extracts were prepared
from two mesothelioma-derived cell lines (Meso 7 T and 8 T) and
NMS controls and subjected to metabolomics using liquid
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(Fig. 4d). Guided by the data from an initial unbiased analysis
which indicated changes in malate and nucleotides (Fig. 4d), we
further interrogated TCA cycle intermediates and nucleotide
biosynthesis. Changes in the TCA cycle (Fig. 4e) were of particular
interest owing to the specific translational upregulation of SDH in
MpM-derived cells (Fig. 1h). Guided by the data from the
untargeted analysis, a targeted approach was applied to further
interrogate pathways of interest (i.e. TCA cycle and nucleotide
biosynthesis). The data show while there are modest differences in
the abundance of the metabolites citrate, alpha ketoglutarate and
succinate, there is a twofold increase in the intracellular
abundance of the metabolite malate (Fig. 4f), which is downstream
of SDH that we show to be translationally upregulated. There was
also an increase in intermediates required for the production of
purines and pyrimidines, such as carbamoyl aspartate and
dihydroorotate (Supplementary Fig. 5, Supplementary data 3).
Stable isotope labelling using 13C6-glucose and 13C5-glutamine
revealed glutamine to be the major carbon source for TCA cycle
intermediates and aspartate, with increased labelling being
observed in Meso 7 T and Meso 8 T compared with NMS cells
(Supplementary Fig. 6A, B). Pronounced labelling of carbamoyl
aspartate was observed from 13C5-glutamine, but not from 13C4-
aspartate, highlighting the relevance of de novo aspartate synthesis
for nucleotides in these cells (Supplementary Fig. 6C).
Targeting mRNA translation reverses the phenotype of MpM.
It was important to establish whether the upregulation of mito-
chondrial protein expression and function was the direct result of
increased expression/activity of the canonical translation
machinery. Such information would provide a way to target MpM
tumour cell growth by limiting the enhanced metabolism and the
global increase in protein synthesis rates, in addition to the
selective targeting of specific nuclear-encoded mitochondrial
proteins. To identify potentially targetable dependencies in the
translation cascade we used a pharmacological approach to
inhibit upstream pathways that signal to translation, in particular
the mTOR axis38 or the direct inhibition of activity/function of
eukaryotic initiation factors (Fig. 5a), that we identified as upre-
gulated in MpM (Figs. 5b, c, Fig. 1e, Supplementary Fig. 2D). To
inhibit the canonical translation machinery in MpM, cells were
treated with hippuristanol to target eIF4A39, 4EGI-140 to target
the interaction of eIF4E with eIF4G, and the MNK inhibitor
EFT508 (Tomivosertib)41 to inhibit eIF4E phosphorylation
(Fig. 5a). Upstream signalling to translation was inhibited using
rapamycin to block mTORC1 or mTORC1 and 2 combined
(using Torin 1 or the clinically relevant AZD201442,43) (Fig. 5a).
The data show that directly targeting the canonical translation
machinery using either 4EG-1 or hippuristanol decreased protein
synthesis rates and reduced cell growth (Fig. 5d–g, Supplementary
Fig. 7A, C). Treatment with EFT508 to inhibit MNK activity had
no effect on protein synthesis or cell growth (Supplementary
Fig. 7E–G). Inhibition of mTORC1 alone with Rapamycin
(Supplementary Fig. 8A) had no significant effect on global
protein synthesis rates in MpM cells (Supplementary Fig. 8B)
recapitulating the ineffectiveness of the rapalog everolimus in
phase II clinical trial44. However, dual targeting of mTORC1 and
2 with Torin1 resulted in a significant reduction in protein
synthesis rates and cell growth (Fig. 5h, i, Supplementary Fig. 8C),
with similar effects growth observed with AZD2014 (Fig. 5j,
Supplementary Fig. 8D). These data are consistent with active-site
mTOR inhibitors such as Torin1 or AZD2014, suppressing
rapalog-resistant mTORC1 outputs, e.g., phosphorylation of 4E-
BP145,46.
We then assessed whether either direct or indirect targeting of
mRNA translation would reduce the abnormal expression of
mitochondrial proteins, which were selectively translationally
upregulated. The data show that combined inhibition of TORC1
and 2 has a greater inhibitory effect on the synthesis of selected
proteins and in addition, decreased the phosphorylation status of
the pro-fission protein DRP1 and expression of MTFP1 (Fig. 5k,
Supplementary Fig. 8E, F, Supplementary Fig. 9). There was a
decrease in SDH expression following treatment of cells with
4EGI-1 (Supplementary Fig. 7B), but no change following
treatment with hippuristanol or EFT508 (Supplementary Fig. 7D,
H). Taken together, these data suggest that translation of selected
mitochondrial proteins is particularly dependent on the eIF4E
and eIF4G interaction, which is inhibited by targeting mTORC1
and 2 (Fig. 5l, Supplementary Fig. 9) or using 4EGI-1. Although
there was a strong effect on cell growth with mTORC1 and 2
inhibition, this did not induce apoptosis (Supplementary Fig. 10).
To address whether mTOR signalling correlated with the
expression of mitochondrial proteins in human tumour material,
tumour TMAs were probed with antibodies directed against
phosphorylated rpS6 and SDH and the data show a highly
significant positive correlation (Fig. 5m).
Inhibition of translation reverses mitochondrial morphology
and changes metabolic outputs. To examine the metabolic effects
of inhibition of mTORC1 and 2 on mitochondrial function, sea-
horse analysis was used to determine changes in oxidative phos-
phorylation. There was a decrease in OCR in cells, consistent with
a reduction in mitochondrial function (Fig. 6A, B). We then
explored whether this similarly changed the metabolic profile
(Fig. 6c, Supplementary data 4). Metabolomics revealed that
MpM-derived cell lines treated with mTORC1 and 2 inhibitors
resulted in a reduction in malate and TCA-derived metabolites,
Fig. 3 Aberrant synthesis of mitochondrial components and alterations in phosphorylation of fission proteins changes mitochondrial morphology and
function. a Representative electron micrographs of primary MpM cell lines (Meso 7 T, Meso 8 T, Meso17T) and control cells (NMS). Scale bar 1 μm. b The
average number of enlarged particles per field. In all, 19–23 different micrographs (for n= 369 mitochondrial particles) were analysed per sample. Error
bars represent SD and significance was assessed using Mann–Whitney test, p values are shown on the bar graphs. The average number of elongated
particles per field. In all, 19–23 different micrographs (n= 369 mitochondrial particles) were analysed per sample. Error bars represent SEM and the
measure of the centre of the error bars is the mean, significance was assessed using Mann–Whitney test p values are shown above the bars. c Confocal
images of primary MpM cells or healthy mesothelial control, stained with DAPI (blue-nuclei) and ATPB (red-mitochondria). Scale bar 20 μm or 4 μM for
the call outs. d The mitochondrial networks in the samples from c were assessed in terms of the extent of elongated, mixed or enlarged/fragmented
mitochondria and the data represented as pie charts, (black sections = elongated, light grey sections = mixed and dark grey = enlarged). The significance
of changes in the elongated mitochondrial network was assessed using two-sided unpaired Student’s t test NM vs tumour cell lines. P values are shown
above the pie charts. e Western blot analysis of eight primary cell lines derived from patients with MpM and from untransformed mesothelium (NM),
which were probed with antibodies against phospho-Ser616 DRP, DRP1, MTPF1 and Mitofusin2. Beta-actin was used as a sample integrity control. Source
data are provided as a Source Data file. f Densitometric analysis of the western blots in data shown in Fig. 2e. Protein levels in MpM-derived cell lines are
compared to NM control cells. Error bars represent standard deviation, and the measure of the centre of the error bars is the mean (n= 8 biological
repeats). Significance was assessed using a two-sided unpaired student’s t test with multiple comparisons, p values are shown on the bar graphs.
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Fig. 4 Metabolic changes in MpM-derived cells. a The oxygen consumption rate (OCR) of primary MpM and NM control cells was measured in the
seahorse extracellular flux assay. The vertical dashed lines indicate when oligomycin (a), FCCP (b) and rotenone + antimycin A (c) were injected. Error
bars represent standard deviation and the measure of the centre of the error bars is the mean (n= 6 where n= number of independent biological repeats
of the oxygen consumption rate experiments). b The basal respiration of primary MpM and NM control cells was measured as the OCR value before
oligomycin injection. Error bars represent standard deviation and the measure of the centre of the error bars is the mean. Significance was assessed using a
two-tailed unpaired Student’s t test adjusted for multiple comparisons (n= 6 where n= number of independent biological repeats of the basal respiration
rate measurements, p values are shown on the bar graphs). c The maximal respiration of primary MpM and NM control cells was measured as the highest
OCR value after FCCP injection. Error bars represent standard deviation and the centre of the error bars is the mean. Significance was assessed using
unpaired two-sided student’s t test adjusted for multiple comparisons (n= 6, n= number of biological repeats of maximal respiration rate measurements, p
values are shown on the bar graphs). d Cell extracts were prepared from Meso 7 T, Meso 8 T and NMS cells and analysed by LC-MS/MS. Untargeted data
analysis revealed increased intracellular abundance of malate, various intermediates of de novo pyrimidine synthesis, and derivatives of pyrimidine
nucleotides in mesothelioma cells. Red dots indicate metabolites for which intracellular abundance was altered significantly and coherently in both cell lines
compared with NMS cells (absolute log2 fold change ≥0.58; adjusted p value < 0.05 (Benjamini–Hochberg), ANOVA). e Schematic to show the TCA cycle.
f Data analysis was performed to determine the intracellular abundance of citrate, α-ketoglutarate, succinate and malate. Data represent the mean ± SD
obtained and the centre of the error bars represents the mean. Significance was assessed using two-sided unpaired two-sided student’s t test adjusted for
multiple comparisons, p values are shown on the bar graphs. NMS= normal mesothelial cells, blue bars, Meso 7 T is red bars and Meso 8 T are the
green bars.
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consistent with the reduced mitochondrial respiration (Fig. 6d)
and a decrease in nucleotides and their precursors (Fig. 6e, f).
There were also significant increases in free intracellular amino
acids, consistent with the inhibition of protein synthesis (Fig. 6c)
and also likely to be influenced by induction of autophagy
(although this has not been explored further).
To explore whether inhibition of translation reversed the other
aberrant mitochondria characteristics observed in MpM, cells were
treated with mTORC1 and 2 inhibitors. Thus, following treatment
with Torin1 we observed a reduction in mitochondrial 2D section
size (Fig. 6g, h; Supplementary Fig. 11), the restoration of the
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Inhibition of translation in ex vivo patient explants, and
in vivo in mouse models, inhibits tumour cell proliferation. We
then explored the effect of translation inhibition on MpM tumour
cell growth using ex vivo patient samples and in vivo mouse
models of asbestos-induced MpM. To determine whether the
inhibitory in vitro cell growth effects could be recapitulated
ex vivo, mTORC1 and 2 were inhibited (using either AZD2014 or
Torin 1) in explants from freshly resected human tumours;
samples were stained for cytokeratin (as a marker of tumour
area), puromycin (to assess protein synthesis) and phospho rpS6,
ATP5A, SDH and Ki67 (Fig. 7a). Following inhibition of
mTORC1 and 2 there was a decrease in protein synthesis rates in
the tumour samples as measured using puromycin incorporation
assays (Fig. 7b and Supplementary Fig. 12B), consistent with a
change in the phosphorylation status of rpS6 (Fig. 7b and Sup-
plementary Fig. 12A), and in parallel there was a decrease in
expression of SDH and ATP5A (Fig. 7b and Supplementary
Fig. 12C, D), and a concomitant decrease in tumour cell growth
as shown by Ki67 staining (Fig. 7b and Supplementary Fig. 12E).
Inhibition of eIF4A correlated with a reduction in staining for
puromycin and Ki67, however, there was no decrease in ATP5A,
SDH or phospho rpS6 (Supplementary Fig. 12F–J). Given these
data, we reasoned that the most effective way to target meso-
thelioma in vivo was to simultaneously inhibit mTORC1 and
mTORC2. In this regard, the dual mTORC1 and 2 inhibitor
AZD2014 (vistusertib) has been trialled clinically43,47,48. How-
ever, as cancer cells can escape the requirement of signalling
through mTOR by increasing nutrient uptake49 and inhibition of
mTORC1 can result in feedback activation of the PI3K/AKT
axis50,51 (Supplementary Fig. 12L), for longer-term targeting of
this pathway in tumours it is advantageous to use this drug in
combination with a PI3K inhibitor, such as AZD818642,52,53
(Supplementary Fig. 12K), a combination that has been trialled
clinically without unacceptable toxicity54. This combination is
therefore most relevant in terms of putative human intervention
strategies in the future. In agreement with previous studies,
although AZD8186 has no effect on its own (Supplementary
Fig. 12M, N) combining AZD2014 with AZD8186 increased the
inhibition of signalling through mTORC1 and 252,53, particularly
at later time periods (Supplementary Fig. 12K–N; e.g., compare
lane 12 and 13 in Supplementary Fig. 12L).
We then tested this combination for its potential therapeutic
benefit in vivo, using a genetically engineered mouse model of Cre-
inducible mesothelioma described previously55, which was adapted
to include the disease-relevant asbestos-driven inflammatory land-
scape. Adult mice bearing homozygous floxed alleles for Tp53 and
Nf2 and constitutively deleted for Cdkn2a (Cdkn2a−/−; Nf2fl/fl;
Tp53fl/fl termed “CNP”) were intrapleural injected with 107 pfu
Lenti-Cre, followed after 10 days by a single intrapleural injection of
25 μg of long fibre amosite asbestos, and allowed to age for a further
50 days. The mice were treated with AZD8186 and AZD2014
combination54. Starting from day 60 post-Lenti-Cre induction, mice
were treated daily with a combination of AZD8186 (50mg/kg twice
daily) and AZD2014 (15mg/kg, once daily), or vehicle control, and
maintained until symptoms required humane euthanasia. The
combination of AZD2014 and AZD8186 yielded a significant
Fig. 5 Aberrant signalling through mTOR correlates with increased protein synthesis in MpM. a Schematic summary showing mTORC1 and
mTORC2 signalling pathways upstream of protein synthesis regulation. b Western blot analysis of eight primary cell lines derived from patients with MpM
and from untransformed mesothelium (NM), which were probed with antibodies against Akt and phosphorylated Akt, as a marker for mTORC2 activity,
and 4EBP1 and phosphorylated 4EBP1, p70S6K and phosphorylated p70S6K, as a marker for mTORC1 activity. Actin was used as a sample integrity control.
Source data are provided as a Source Data file. Experiments were repeated on three occasions and similar data were obtained in each case. c Western blot
analysis of eight cell lines derived from patients with MpM and from a pool of untransformed mesothelium (NMS), which were probed with antibodies
against eEF2 and phosphorylated eEF2. Beta-actin was used as a sample integrity control. Experiments were repeated on three occasions. d Primary MpM
cells (Meso 7 T or Meso 8 T) were treated with 25 μM 4EGI-1 and the rate of cell growth was assessed over a 72 h time period with a crystal violet assay.
Error bars represent standard deviation, the centre of the error bars is the mean (n= 4 where n= number of biological repeats of growth rate
measurements as determined by change in absorbance). Blueline is untreated, red line treated with 25 μM 4EGI-1. e Primary MpM cells (Meso 7 T or Meso
8 T) were treated with 25 μM 4EGI-1. Puromycin incorporation from n= 3 independent experiments (representative in Supplementary Fig. 7 A). Error bars
represent standard deviation and significance was assessed using unpaired Student’s t test, p values are shown on the bar graphs. f Primary MpM cells
(Meso 7 T or Meso 8 T) were treated with 100 nM Hippuristanol and the rate of cell growth was assessed over a 72 h time period with a crystal violet
assay. Error bars represent standard deviation and the centre of the error bars represents the mean (n= 4 where n= number of biological repeats of
growth rate measurements). Blueline is untreated, red line treated with 100 nM Hippuristanol. g Primary MpM cells (Meso 7 T or Meso 8 T) were treated
with 100 nM Hippuristanol. Puromycin incorporation from n= 3 independent experiments (representative in Supplementary Fig. 7 C). Error bars represent
standard deviation and the centre of the error bars represents the mean. Significance was assessed using two-sided unpaired Student’s t test adjusted for
multiple comparisons, p values are shown on the bar graphs. h Primary MpM cells (Meso 7 T or Meso 8 T) were treated with 100 nM Torin 1 and the rate
of cell growth was assessed over a 72 h time period with a crystal violet assay. Error bars represent standard deviation, with the centre of the error bar the
mean (n= 3, n= number of independent biological repeats of growth rate measurements). Blueline is untreated, red line treated with 100 nM Torin 1. i To
assess protein synthesis rates, primary MpM-derived cell lines Meso 7 T and Meso 8 T were incubated with 100 nM Torin 1 for 30m, followed by 33 μCi of
35 S methionine and the rate of incorporation over a 30m period was assessed. Error bars represent standard deviation and the centre of the error bars
represents the mean. (n= 3) and where n= number of independent biological repeats. Significance was assessed using a two-sided unpaired Student’s t
test adjusted for multiple comparisons, p values are shown on the bar graphs. j Primary MpM cells (Meso 7 T or Meso 8 T) were treated with 100 nM
AZD2014 and the rate of cell growth was assessed over a 72 h time period with a crystal violet assay. Error bars represent standard deviation, the centre of
the error bars represents the mean (n= 8, n= number of independent biological repeats of growth rate measurements). Blueline is untreated, red line
treated with 100 nM AZD2014. k Western blot analysis of primary MpM cell lines (Meso 7 T and Meso 8 T) treated with 100 nM Torin 1 for 24 h and
probed with antibodies to assess changes in mTOR pathway, mitochondrial protein expression and mitochondrial dynamics. Actin was used as a sample
integrity control. l m7GTP pull-down assay was performed on primary MpM cell lines (Meso 7 T and Meso 8 T), which were treated with 100 nM Torin 1
for 30m. Input extracts and cap analogue pull-downs were probed with antibodies against eIF4G and 4EBP1. eIF4E was used as an input and pull-down
control. Experiments were repeated on three occasions. m Correlation analysis between rpS6 phosphorylation (mTOR activity) and SDH expression in
mesothelioma TMAs. Of the n= 812 individual TMA cores, 723 (89.04%) had a Phosho rpS6 H-score and 734 (90.39%) had an SDH H-score. SDH
H-score was split into four equally sized groups and Spearman’s correlation analysis was performed for Phospho pS6 H-score against these groups. From
n= 689 cores which had both a pS6 and SDH H-score, Spearman’s correlation coefficient was 0.172. The box plots show the box from the first quartile to
the third quartile. The middle line represents the median. The whiskers go up to the maximum and minimum values.
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extension of survival (Fig. 7c). Immunohistochemistry analysis of
phospho rpS6 in the tumour region shows a reduction consistent
with mTOR inhibition (Supplementary Fig. 13A, B).
Taken together, these data strongly suggest that inhibition of
translation and energy production by targeting mTORC1 and 2
would restrict tumour cell growth in patients with MpM and
provide a viable treatment option to extend lifespan, which is on
average less than 18 months from diagnosis.
Discussion
MpM is not associated with activation of any classical proto-
oncogenic drivers, implicating epigenetic and regulatory mechan-
isms such as post-transcriptional dysregulation in the aberrant cell
growth phenotype. Our data show that in MpM there is upregu-
lation of global mRNA translation with a striking superimposed
selective increase in the synthesis of ribosomal proteins, themselves
central components of the canonical translational apparatus, and
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mitochondrial and translational machinery proteins is seen in pri-
mary human tumour tissue, and both are related to tumour cell
proliferation rates (Fig. 2). In MpM cells, changes in mitochondrial
shape and connectivity were related to alterations in key Krebs cycle
metabolites, which correlate with the synthesis of key metabolic
enzymes (Figs. 3–4). In particular, increased expression of SDH
correlates with enhanced production of TCA intermediates, leading
to the production of pyrimidine and purines required for cell
growth (Fig. 4). To identify ways in which to reduce mRNA
translation and mitochondrial output, protein synthesis was tar-
geted by either directly inhibiting the canonical translation
machinery or upstream signalling pathways. Interestingly, drugs
that reduce the binding of eIF4G to eIF4E, either through increased
sequestration of eIF4E by eIF4E-BP1, or by direct interference
decouple the link between translation, synthesis of ribosomal
components and mitochondrial proteins (Figs. 4–6). Thus, while
treatment with 4EGI-1, Torin1 and hippuristanol reduced global
protein synthesis by ~50% and ~75%, respectively, the data show
that treatment with either Torin1 or 4EGI-1 reduces the expression
of SDH, (Fig. 5k, Supplementary Fig. 9, Supplementary Fig. 7B),
whereas there was no effect with hippuristanol (Supplementary Fig.
7D), despite the greater reduction in global protein synthesis.
Moreover, mTOR inhibition has a differential effect on the synth-
esis of additional mitochondrial proteins with a decrease in the
expression of ATP5, and NDUFB8, but no effect in the expression
of the fission protein DRP1 (Fig. 5k, Supplementary Fig. 9).
Interestingly, the lack of reduction in expression of mitochondrial
proteins in the presence of the eIF4A inhibitor hippuristanol is
consistent with data that showed that selected mTOR-sensitive
mRNAs encoding proteins with mitochondrial function had short
5′UTRs, and lacked a 5′ TOP motif and were relatively insensitive
to eIFA4A156. And additional studies, which showed that eIF4A
depletion stimulates mTOR and does not affect the translation of
mRNAs with short 5′ UTRs, including components of the electron
transport chain that contain the TISU element57. It is likely that
eIF4A reduces cell growth via additional mechanisms, and this is
the subject of further studies.
These data are supported by earlier elegant studies in animal
model systems that showed that mTORC1 controls mitochon-
drial activity and biogenesis by selectively promoting the trans-
lation of nuclear-encoded mitochondria-related mRNAs via
inhibition of 4EBPs58. In addition, it has been shown that
mitochondrial fission is linked by mTORC1 signalling to 4EBP1-
mediated translational regulation of MTFP159 and consistent
with these studies, in MpM the mitochondria fission driven by
mTORC1 and 2 correlates with DRP1 phosphorylation status
(Figs. 3 and 5), and inhibition of this pathway significantly nor-
malised the morphology of the mitochondrial network, and
restored mitochondrial metabolism (Fig. 6). Crucially, we also
demonstrate that combined mTORC1 and 2 inhibition impacts
on cell growth of cultured and ex vivo tumour tissue and sig-
nificantly extends the survival of mice with asbestos-induced
mesothelioma (Fig. 7).
Development of MpM is associated with the loss of tumour
suppressor genes, in particular, NF211,13–15 and CDKN2A11,17
both of which were deleted/silenced in the primary cells used in
our experiments, and there is evidence linking the loss of these to
translational dysregulation in a way that is consistent with our
observations. A number of studies have linked the loss of NF2,
which encodes the protein Merlin, to increased signalling through
mTOR60–63. Activation of signalling through mTOR would
enhance protein synthesis rates, and given our data, the pro-
duction of mitochondrial proteins to provide energy for this
process. Epigenetic silencing and loss of p19/Arf precede the
development of MpM in mice. Arf has a central role in the
control of ribosome biogenesis and represses these processes
either directly through its interaction with nucleophosmin64,65 or
indirectly by controlling TTF-I localisation and repressing the
transcription of rRNA genes66. A combination of loss of Arf and
increased synthesis of ribosomal proteins identified in our study
would increase net ribosome biogenesis, which is essential for
tumour cell growth.
Taking the above into consideration, we suggest that the
observed post-transcriptional cytoplasmic alterations in the MpM
Fig. 6 TORC1 and 2 inhibition reverse metabolic effects. a Primary MpM cells Meso 7 T and Meso 8 T were treated with 100 nM Torin1 or left untreated
for 18–20 h. The oxygen consumption rate (OCR) was measured in the SeaHorse extracellular flux assay. The vertical dashed lines indicate when
oligomycin (a), FCCP (b) and rotenone + antimycin A (c) were injected. Error bars represent standard deviation, the centre of the error bar is the mean
(n= 6 independent biological repeats). b The basal respiration from A was measured as the OCR value before oligomycin injection. The maximal
respiration from A was measured as the highest OCR value after FCCP injection. Error bars represent standard deviation and the centre of the error bar is
the mean. Significance was assessed using two-sided unpaired student’s t test adjusted for multiple comparisons, n= 6 independent biological repeats. P
values are shown on the bar graph. c Cell extracts were prepared from Meso 8 T cells treated with vehicle or 100 nM AZD2014 for 24 h to inhibit mTORC1
and mTORC2, and analysed for metabolites representing multiple metabolic pathways. Volcano plot showing changes in intracellular metabolite
abundance upon treatment with AZD2014. Red dots indicate metabolites for which intracellular abundance was altered significantly. Three biological
experiments, each with three technical replicates absolute log2 fold change ≥0.58; two-sided paired t test was used with Benjamini–Hochberg correction to
log2 transformed and centred data using R. d Intracellular abundance of TCA cycle metabolites: citrate, α-ketoglutarate, succinate, malate. Data represent
the mean ± SD obtained from three biological experiments, each with three technical replicates. Significance was assessed using a two-sided Student’s t
test with Benjamini–Hochberg correction, p values are shown on the graph. Blue bars untreated, red bars treated with 100 nM AZD2014. e Intracellular
abundance of pyrimidine synthesis intermediates: carbamoyl aspartate, dihydroorotate, orotate, dTTP. Data represent the mean ± SD obtained from three
biological experiments, each with three technical replicates. Significance was determined using two-sided Student’s t with Benjamini–Hochberg correction,
p values are shown on the graph. Blue bars untreated, red bars treated with 100 nM AZD2014. f Intracellular abundance of dATP. Data represent the mean
± SD obtained from three biological experiments, each with three technical replicates. Significance was assessed using paired two-sided student’s t test
with Benjamini–Hochberg correction, p values are shown on the graphs. g Electron micrographs of primary MpM cell lines (Meso 7 T and Meso 8 T)
treated with 100 nM Torin 1 for 48 h. Scale bar 1 μm. h Enlarged and elongated mitochondria per field in G were calculated. In all, 19–23 different
micrographs (for 369 mitochondrial particles) were analysed per sample. Error bars represent SEM and significance was assessed using a Mann–Whitney
test, p values are shown. i Confocal images of primary MpM cells Meso 7 T and Meso 8 T treated with 100 nM Torin 1 for 24 h or left untreated, stained
with DAPI (blue-nuclei) and ATPB (red-mitochondria). Scale bar 20 μm. Experiments were repeated on three independent occasions. j The mitochondrial
networks in the samples from i were assessed in terms of the extent of elongated, mixed or enlarged/fragmented mitochondria and the data represented
as pie charts, (black sections= elongated, light grey sections=mixed and dark grey= enlarged). The significance of changes in the elongated
mitochondrial network was assessed using an unpaired two-sided student’s t test adjusted for multiple comparisons. Untreated vs Torin 1, p values are
shown on the bar graphs.
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cells are the result of the loss of key tumour suppressor genes and
facilitate tumour cell growth in the absence of classical proto-
oncogenic drivers. Therefore, it is attractive to devise therapeutic
regimes that target upregulated ribosome biogenesis, mRNA
translation and the abnormal mitochondria which support these
processes. Here, we show that combined inhibition of mRNA
translation by mTORC1 and mTORC2 targeting significantly
reduces tumour cell growth in cell lines and in ex vivo patient
material and that a clinically relevant combination of the bispecific
inhibitor AZD2014 with AZD8186 significantly extended survival
of transgenic mice with MpM. Our data suggest that treatment
with these drugs by targeting both mitochondrial fission/fusion
and the selective synthesis of nuclear-encoded mitochondrial
proteins and components of the canonical translation machinery
reduces aberrant cell growth and leads to lifespan extension.
This biologically rational approach of the dual targeting of
mTORC1 and mTORC2 offers hope for effective targeted therapy
in this unique and devastating malignancy.
Methods
All research was carried out in compliance with all relevant ethical regulations for
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Fig. 7 mTORC1 and 2 inactivation inhibits tumour cell growth ex vivo and in mouse models of MpM. a Representative sections of mesothelioma explants
stained with the indicated antibody. Cytokeratin staining was used to identify tumour areas within the explants. Scale bar 1 μm, 200 μm for the call outs.
b Mesothelioma explants were cultured for 72 h with 100 nM AZD2014 or with vehicle. H-score quantification of IHC staining within tumour areas is
performed by Visiopharm® software. Mann–Witney significance test was performed (two patients, n= 8 explants, each p values are shown on the graph).
The box plots show the box from the first quartile to the third quartile. The middle line represents the median. The whiskers go up to the maximum and
minimum values. c Adult mice (Cdkn2a−/−;Nf2fl/fl;Tp53fl/fl) were intrapleurally injected with 107 pfu Lenti-Cre, followed after 10 days by a single
intrapleural injection of 25 μg of long fibre amosite asbestos and allowed to age for a further 50 days. The mice were treated with AZD2014 + AZD8186
(n= 9 mice) or vehicle control (n= 9 mice), from d60 post-viral induction of floxed alleles. Graph shows survival from the first day of treatment
(Mantel–Cox log-rank test).
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Material availability. All unique/stable reagents generated in this study are
available from the lead contact with a completed Materials Transfer Agreement.
Cell culture. Mesothelioma-derived primary cells were isolated as described32 in
addition to 13 T, which was derived at the same time using the same methodology
and displays the same mesothelioma characteristics. Mesothelioma-derived pri-
mary cells were cultured in Roswell Park Memorial Institute Medium (RPMI)-1640
growth media supplemented with L-glutamine (2 mM), penicillin (100 U/ml),
streptomycin (100 μg/ml), hEGF (20 ng/ml), hydrocortisone (1 μg/ml) and 10%
FBS at 37 °C and 5% CO2. Primary untransformed mesothelium cells NM (single
donor) and NMS (pool of four donors) were purchased from Zenbio and main-
tained according to the manufacturer’s indications. For all experiments, Meso-
thelioma primary tumour cells and untransformed mesothelium controls were
plated in RPMI with L-glutamine (2 mM), 10% FBS, but with no additional growth
factors and adapted at 37 °C and 5% CO2 for 18 h, before being treated as indicated.
Cell growth was measured by crystal violet staining. Cells were plated in 96 wells at
least n= 3 per condition. Cells were treated and then fixed in 3% paraformalde-
hyde (PFA) (Sigma), 2% sucrose in PBS 1× solution for 10 m at 25 °C, stained with
0.05% crystal violet, washed in water and dried at 25 °C. The dye was solubilized in
10% acetic acid and the absorbance at 540 nm was measured with a Power Wave
XS2 plate reader (BioTek).
35 S methionine incorporation and puromycin incorporation. Cells were pulsed
with 35S Met/Cys for 30 m at 37 °C in a 5% CO2 incubator. Met/Cys incorporation
was stopped by chilled PBS wash. Cells were lysed in radioimmunoprecipitation
assay buffer, and proteins were precipitated with Trichloroacetic Acid (TCA) 35S.
Met/Cys incorporation into newly synthesised proteins was evaluated by scintil-
lation counting. Bicinchoninic Acid (BCA) assay was performed on the sample
extracts to normalise the protein concentration.
Puromycin incorporation into nascent polypeptides was performed according
to the SUnSET method67. In brief, primary cells were incubated with 10 μg/ml of
puromycin for 10 m, before being lysed and protein immunoblotted with 12D10
monoclonal antibody to puromycin (Millipore). Equal loading was visualised by
staining with Ponceau S (Sigma). Tumour explants were incubated with 10 μg/ml
of puromycin for 30 m, before being fixed with 10% neutral buffered formalin
(Sigma) and processed for immunohistochemistry.
Polysome profiling. i) Sucrose density gradient centrifugation and RNA detection
MM cells were treated with 100 μg/ml cycloheximide (CHX) for 3 m prior to
harvesting. Cells were lysed in gradient buffer (300 mM NaCl, 15 mM MgCl2, 15
mM Tris pH 7.5, 100 μg/ml CHX) plus 1% Triton X-100. Post-nuclear
supernatants were layered on 10–50% (w/v) sucrose gradients dissolved in gradient
buffer. Gradients were centrifuged at 240,000 × g for 2 h at 4 °C in an SW40Ti rotor
(Beckman Coulter), then separated through a live optical density 254 nm UV
spectrometer (Isco). Gradients were fractionated with continuous monitoring at
254 nm. RNA was isolated from each fraction. First, the volume was adjusted to 2
ml by the addition of H2O, followed by the addition of 3 ml of 8M guanidine HCL.
Next, 5 ml of 100% ethanol was added, fractions were cooled to −20 °C and then
centrifuged at 24,000 × g for 25 min to collect the RNA. The pellets were washed
with 75% ethanol, resuspended in 400 ml of TE, pH 7.5, reprecipitated using 0.3 M
NaOAC and 2.5 volumes of ethanol. The pellets were washed with 75% ethanol and
resuspended in 100 ml of TE, pH 7.5 27,27. RNA was extracted from fractions
using Trizol reagent (Invitrogen) according to the manufacturer’s instructions.
QuantiTect probes (QIAGEN) for ribosomal proteins mRNAs RPS6, RPS15A,
RPL7A, RPL15, RPL24, initiation factors EIF4A1 and EIF4G2 (Dap5),
mitochondrial proteins ATP5A1, COX8A, COX7B, UQCRC2 and SDHB,
transcript NEO1 and DST, were used according to the manufacturer’s instructions
in order to detect the relative mRNA abundance in the gradient fractions.
QuantiTect assay (QIAGEN) for ACTB and PABP mRNAs was performed in order
to confirm the position subs and polysomes. The polysomal/subpolysomal ratio
was determined by Fiji software as the area under the curve.
1. Preparation of fluorescently labelled cDNA for microarray hybridisation
2. Microarrays used were Agilent 8×60k Human Gene Expression arrays
(Agilent Technologies LDA UK Ltd.). Equal proportions of RNA from pooled
subpolysomal fractions and pooled polysomal fractions were fluorescently
labelled, using the Agilent Low Input Quick Amp Labelling Kit, two-colour
(Agilent Technologies LDA UK Ltd.). Following hybridisation, the arrays
were scanned using an Agilent SureScan High-Resolution scanner and
Agilent Feature Extraction software was applied to the resulting images.
3. Array analysis
Raw array data (two-colour, with dye swaps, eight tumour samples and two
controls, three repeats) were background corrected using the “normexp” method in
the limma R package68. The polysome/subpolysome ratios for each probe (M values,
log2(red/green)) were compared between the tumour samples and the control
samples using RankProd69. This is a nonparametric approach that assesses the
significance of changes in rank. RP identifies differentially translated probes as
separate up- and downregulated lists, and, for each probe, calculates a pfp (percentage
of false prediction) which can be used to select significant probes for further study. By
way of detailed explanation for this analysis: every gene has a fold change value (FC)
between Tumour and Control (see column G in Supplementary Fig. 1). Per every
gene, RankProd generates two rankings and two P values (see Supplementary Fig. 1).
Column K is the position (rank) of the gene in the UP list, column I is the P value for
the gene for being upregulated. Column S is the gene rank in the Down list, column Q
is the P value for being downregulated. See, for example, in row 33 of Supplementary
Fig. 1, the probe A_23_P329573 for Beta2 Integrin gene ITGB2 (NM_000211). The
probe is 6.4 times more intense in Tumour vs Control (Fold Change); the probe is in
position 44 in the UP list (see column K) and in position 33265 in the Down list
(column S). The probability of Beta2 Integrin gene being in the up list is 2.85E-07 (P
value in column I), corrected for multiple testing (PFP 0.000227273 in column H).
The probability for Beta2 Integrin gene being downregulated is extremely low
(P value in column Q and PFP in column P are proximal to 1). Data were
considered to be significantly changing if the fold change was at least two at pfp
<0.2. This analysis pipeline from raw arrays to lists of significantly changing probes
is available as the INCATome R package from CRAN70.
GO term analysis. Lists of significantly up- and downregulated transcripts were
uploaded to the online tool bioprofiling.de71. Gene Ontology (GO) analysis was
performed according to the method described in the online tool. The upregulated
genes (list A) and a reference list (list B: all the genes in the genome) are compared.
For each GO class f from the set F (all the GOs) the number of genes that have been
annotated with f in list A and list B are counted and compared. Then, the null
hypothesis H0 (genes that belong to set A are independent of having attribute f) is
tested. The output table is provided as Supplementary data 2 (data are expressed in
European Number Format). The hierarchical clustering based on Pearson corre-
lation and the heatmap was generated with GeneSpring GX (Agilent).
UTR analysis. The 5′ UTR, 3′ UTR and CDS sequences for each RefSeq72 tran-
script, for each gene found on the microarray chip, were retrieved from GenBank73
records (in-house script). The 5′ UTR sequences were searched for TOP/TOP-like
motifs and upstream open-reading frames (uORFs) (in-house scripts). TOP motifs
were defined as C[CT]74 at the start of the 5′ UTR; if found at positions 2 to 5 from
the start of the 5′ UTR they were designated TOP-like75. uORFs were defined by an
AUG start codon in the 5′ UTR, an in-frame stop codon preceding the end of the
main CDS, and a length of at least 9 nt76. The 3′ UTR sequences were investigated
for the presence of AU-rich elements (in-house script). AU-rich elements were
defined as TATTTAT[AT][AT]. The level of structure in each 5′ UTR was cal-
culated using RNAfold from the ViennaRNA Package77. The upregulated and
downregulated lists of significantly changing genes were compared to the rest of the
chip to find any enrichments using χ2 tests for the presence of TOP/TOP-like
motifs, uORFs and AU-rich elements and t tests were used for mean 5′ UTR length
and 5′ UTR mean free energy. The t test carried out on the set of lengths in the
upregulated list against the set of lengths in the rest of the array chip to determine
whether they came from the same population showed a distinct difference between
the pools, with one pool with shorter 5′ UTRs. The list of known TISUs was
explored using Table S2 from Sinvani et al.31.
SDS-PAGE and western blotting. Cell lines extracts were generated and subjected
to protein quantification by BCA (Thermo Scientific). Protein extracts were sub-
jected to electrophoresis on sodium dodecyl sulphate–polyacrylamide gel electro-
phoresis followed by transfer to polyvinylidene difluoride membrane (GE
Healthcare). Proteins were detected with the relevant antisera using either che-
miluminescent reagents (Bio-Rad) or by Odyssey (LI-COR).
Cap m7GTP Sepharose (GE Healthcare) column pull-down was performed on
400 µg of total extracts according to manufacturer instructions. Densitometry was
performed with Fiji (Fiji Is Just ImageJ) software according to standard procedure.
TMA construction and staining. An electronic search of the University Hospitals
of Leicester (UHL) NHS Trust histopathology databases was conducted to identify
all patients aged 18 years or older who underwent surgery for primary malignant
pleural mesothelioma from 2003 to 2014. Surgical procedures included extrapleural
pneumonectomy, extended pleurectomy decortication or more localised resections
that generated fixed tissue at least 50 mm across or at least five formalin-fixed,
paraffin-embedded (FFPE) blocks. All tissue and data used to facilitate the con-
struction of the TMAs were collected under NHS ethics agreement 14/EM/1159
approved by the Northampton committee of the National Research Ethics Service.
Owing to the specific HRA exemption for the need for consent for the use of spare
archival tissue derived from living patients when samples are handled in an
anonymised matter-specific written consent was not required. TMA consist of a
recipient formalin-fixed paraffin-embedded block containing 3 × 1mm donor core
donor samples per case, with 40 cases sampled per TMA block. Initially, whole-
slide images of haematoxylin and eosin-stained archival mesothelioma were cap-
tured at ×40 magnification using the Hamamatsu Nanozoomer XR. Areas con-
taining sufficient tumour material were digitally annotated and corresponding
FFPE blocks were retrieved from the diagnostic archive. Where possible, both
epithelioid and sarcomatoid regions of tumour differentiation were sampled. A
TMA map was produced, 1 mm cores were taken from viable donor blocks and
transposed into a pre-prepared recipient TMA block using a semi-automated
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platform (TMArrayer TM, Pathology Devices). The resulting TMA block was
annealed at 37 °C overnight and cooled to room temperature. In all, 4.5 µm sections
were prepared from the finished TMA for in situ analysis. Immunohistochemical
staining was performed using a chromogenic duplex method, with cytokeratin
(MNF) in yellow to aid tissue segmentation and the signal to be quantitated in
purple. Assays were performed on a Ventana Discovery Ultra staining platform
using the following conditions and counterstained with haematoxylin. Whole-slide
images of stained slides were captured at ×40 magnification using the Hamamatsu
Nanozoomer XR and analysed using Visiopharm® software. Tumour regions were
outlined using a threshold algorithm, and a cytoplasmic H-score was calculated on
cells identified using a decision forest algorithm. Cells were placed into categories
of 0, 1+, 2+ and 3+ using manually set pixel intensity thresholds corresponding to
negative, weak, moderate and strongly stained cells. Automatic H- scores generated
by Visiopharm® software were further validated via manual scoring.
Transmission electron microscopy. Cell pellets were fixed with 2.5% glutar-
aldehyde (GA) and 2% PFA in the NaHCa buffer (100 mM NaCl, 30 mM HEPES,
2 mM CaCl2, adjusted at pH 7.4 with NaOH) for at least 30 min, and then pro-
ceeded to the high-pressure freezing and freeze substitution (Leica EM HPM100
and AFS2, Leica Microsystems, Vienna Austria). In brief, the specimens were
incubated in 0.1% tannic acid in anhydrous acetone at −90 °C for at least 24 h,
washed with pure acetone at −90 °C and substituted in 1% osmium tetroxide, 0.1%
uranyl acetate, and 1% pure water in acetone, with temperature-controlled under
−90 °C for 72 h, at −60 °C for 8 h, at −30 °C for 8 h (with an interval of 30 °C/hr).
After several washing with pure acetone at 4 °C, samples were embedded in Epon
and Araldite mixture (TAAB Laboratories Equipment Ltd., Reading UK). After the
polymerisation at 65 °C for few days, the ultrathin-sections (∼60 nm) obtained by
Ultramicrotome (Leica Ultracut UCT, Vienna, Austria) were mounted in EM grids,
stained with lead citrate and then observed by 200 kV transmission electron
microscope (FEI Talos, Oregon USA) with Ceta-16M CMOS-based camera (4kx4k
pixels under 16 bit dynamic range). For the conventional procedure, the cells were
fixed in the GA/PFA mixture and post-fixed with 0.25% osmium tetroxide/0.25%
potassium ferrocyanide and 1% tannic acid. After being stained in a bloc with 5%
aqueous uranyl acetate, dehydration with a series of ethanol and infiltration were
completed for the plastic embedding in TER (TAAB epoxy resin). A shape
descriptor on Fiji software (https://imagej.net/Fiji) was used to quantify mito-
chondrial parameters (area, minor axis, major axis, circularity) in the micrographs.
Elongated mitochondrial particles are considered when the major axis/minor axis
ratio is higher than 3. Enlarged mitochondrial particles displayed a degree of
circularity > 0.8 and area > 0.5 μm2.
Immunofluorescence and confocal microscopy. MpM primary cells and
untransformed controls cells were grown on a glass coverslip in a six-well culture
plate. Fixation was performed with 3% PFA (Sigma), 2% sucrose in PBS 1× solution
for 10 m at 25 °C. Permeabilization was performed in Hepes-TritonX100 (20 mM
HEPES pH 7.4, 300 mM sucrose, 50 nM NaCl, 3 mM MgCl2, 0.5% TritonX100) for
5 m at 25 °C. After blocking in 2% bovine serum albumin (BSA), cells were
incubated with anti-mitochondrial protein ATPB for 30 m at 37 °C, washed in 0.2%
BSA in PBS, and incubated with proper Alexa Fluor conjugated secondary antibody
(Invitrogen) for 30 m at 37 °C. Nuclei were stained with 4′,6-diamidino-2-pheny-
lindole (Sigma). Confocal images were taken at the equatorial plane of the nucleus
with LSM510 META (Zeiss) equipped with ×63 immersion lens. Images were
acquired with Zen2009 software (Zeiss). The mitochondria network morphology
(elongated, mixed or enlarged/fragmented) was determined per every observed cell,
on at least three fields per condition.
Metabolic change measurement. Rates of oxidative phosphorylation were
determined by measuring the rate of OCR using a Seahorse XF96 extracellular flux
(XF) analyser (Seahorse Bioscience, Billerica, MA, USA). Primary MpM or control
cell lines were seeded in an XF96 cell culture microplate at 4 × 104 cells/well 24 h
before the assay and incubated at 37 °C under 5% CO2 in a humidified atmosphere.
In all, 24 h prior to assay, 1 ml of Seahorse calibrant was added to each well of a
Seahorse XF96 utility plate and the probes on the sensor cartridge were allowed to
soak at 37 °C under CO2-free conditions. 1 h prior to assay, cells were washed three
times in unbuffered bicarbonate and serum-free Dulbecco’s Modified Eagle Med-
ium (pH 7.4) containing 1 mM sodium pyruvate,11 mM glucose and 2 mM glu-
tamax; then covered in media, and incubated for 1 h at 37 °C under CO2-free
conditions. The OCR was measured with the Seahorse XF Cell Mito Stress Test Kit
(Agilent) following the manufacturer instructions.
LC-MS analysis. Samples were analysed on a Q Exactive Plus Orbitrap mass spec-
trometer (Thermo Scientific, Waltham, MA, USA) coupled with a Thermo Ultimate
3000 HPLC system. Sample extracts (5 µl) were injected and metabolites were separated
on a ZIC-pHILIC column (SeQuant, 150 × 2.1mm, 5 µm, Merck KGaA, Darmstadt,
Germany), equipped with a ZIC-pHILIC guard column (SeQuant, 20 × 2.1mm). The
total analysis time was 25m and mobile phase acetonitrile content was decreased from
80% (20% 20mM ammonium carbonate, pH 9.2) to 20% acetonitrile over a 15m
gradient (flow rate: 200 μL/min; column temperature: 45 °C). Ions across a mass range
of 75–1000m/z were collected using the Q Exactive Plus mass spectrometer operating
at a resolution of 70,000 (at 200m/z), with electrospray (ESI) ionisation and polarity
switching. A pooled sample (mixture of all sample extracts) was prepared and analysed
multiple times throughout acquisition as a QC control. The same pooled sample was
analysed separately in positive and negative single ionisation mode using data-
dependent fragmentation (ddMS2) for metabolite identification. Data were acquired
with Thermo Xcalibur software. Data analysis and statistical tests (analysis of variance;
Benjamini–Hochberg) were performed using Compound Discoverer software (Thermo
Scientific v3.1). Retention times were aligned across all sample data files (maximum
shift 2min, mass tolerance 5 ppm). Unknown compound detection (minimum peak
intensity 5e5) and grouping of compound adducts were carried out across all samples
(mass tolerance 5 ppm, RT tolerance 0.7min). Missing values were filled using the
software’s Fill Gap feature (mass tolerance 5 ppm, S/N tolerance 1.5). Metabolite
identification was achieved by matching the mass and retention time of observed peaks
to an in-house database generated using metabolite standards (mass tolerance 5 ppm,
RT tolerance 0.5min), Peak annotations were confirmed using mzCloud (ddMS2)
database search (precursor and fragment mass tolerance of 10 ppm, match factor
threshold 50) and searching predicted compositions (mass tolerance 5 ppm, minimum
spectral fit and pattern coverage of 30% and 90%, respectively) against the HMDB
database. Based on data collected on the same system for commercial standards, further
analysis of metabolites was performed using Thermo TraceFinder v4.1 software.
Intracellular metabolites were normalised to the average number of cells collected from
three wells that were experimentally identical to the ones used for metabolite extraction.
The statistical analysis of the data showing the metabolic effects of Torc1 and Torc2
inhibition was performed applying a paired t test with Benjamini–Hochberg correction
to log2 transformed and centred data using R. The outputs are shown in supplementary
data 3 and 4.
Stable isotope labelling using 13C6-glucose, 13C5-glutamine and 13C4-
aspartate. Cells were seeded in triplicate in six-well plates at 50,000 cells per well
(7 T and 8 T) or 100,000 cells per well (NMS) in 2 ml of RPMI (supplemented with
L-glutamine (2 mM), hEGF (20 ng/ml), hydrocortisone (1 μg/ml) and 10% FBS).
After 24 and 48 h, 2 ml of the culture medium was added. After 72 h, the culture
medium was changed to 7 ml supplemented RPMI containing 150 μM 13C4 L-
aspartic acid, 2 mM 13C5 L-glutamine, 11.11 mM 13C6 D-glucose (Sigma) or
without tracer. Cells were extracted after 24 h in 400 μl of ice-cold extraction
solution, and samples were analysed by LC/MS as described above.
Collection of clinical specimens for ex vivo samples. Human investigations were
performed after Research Ethics Committee approval (LREC 08/H0406/226).
Resected mesothelioma specimens were collected with the patient written consent.
All patients underwent surgery for radical decortication without prior che-
motherapy or radiotherapy. Solid tumours were immediately immersed in ice-cold
RPMI-1640 supplemented with penicillin (100 U/ml), streptomycin (100 μg/ml)
and 10% FBS. Samples were transported to the laboratory for primary cell culturing
within 1 h of collection. Tumours were processed in order to obtain small tumour
blocks (~1–3 mm in diameter) and then transferred into a six-well plate (eight
blocks per well) in the above-mentioned medium at 37 °C and 5% CO2. Blocks
were treated with 100 nM Torin1, 100 nM Hippuristanol, 100 nM AZD2014 or 250
nM AZD8186 for 72 h and then fixed in 10% neutral buffered formalin (Sigma).
Immunohistochemical staining for Ki67, pospho-Ser240/244 rpS6, puromycin
(12D10), ATP5A and SDH were performed using DAB (3,3′- Diaminobenzidine);
haematoxylin was used as counterstain. Cytokeratin (MNF) was used to identify
tumour areas within tumour blocks. Quantification of Ki67 positive cells and
quantifications of pospho-Ser240-244 rpS6, puromycin, ATP5A and SDH staining
intensities within tumour area was performed by using Fiji software or H-scores
were generated automatically by Visiopharm® software.
Animal experimentation. All experiments involving mice were approved by the
local animal welfare committee and conducted under UK Home Office licence,
PE47BC0BF (DJM, Glasgow) and were compliant with the ARRIVE guidelines
(https://www.nc3rs.org.uk/arrive-guidelines). Mice were maintained on a constant
12 hr light/dark cycle under controlled climate (19–22 °C; 45–65% humidity), fed
and watered ad libitum and all were mixed background (FVBN and C57Bl/6). Mice
bearing the combination of target alleles Cdkn2a−/−;Nf2fl/fl;Tp53fl/fl were gener-
ously provided by Anton Berns, Netherlands Cancer Institute (NKI)55. Genotyping
was performed by Transnetyx Inc. Tumour initiation was induced in young adult
mice (aged 8–10 weeks) and mice were maintained until predefined humane
clinical endpoints were reached. Lentivirus expressing Cre recombinase was pur-
chased from the University of Iowa vector core facility. Long fibre amosite asbestos
was generously provided by Rodger Duffin (MRC Inflammation Unit, Edinburgh).
Intrapleural injection of asbestos was carried out by injection directly into the
pleural space without perforating the lungs by the addition of a sleeve over the tip
of the 27-Gauge needle; this prevented the needle from passing through the pleural
space into the lungs20. AZ8186 and AZ2014 were supplied by Astra Zeneca under
MTA/RCA with the CRUK Beatson Institute. Drugs were dissolved and admi-
nistered in 0.5% HPMC, 0.1% Tween 20, H2O vehicle. Both males and females
were included on all treatment and control arms. AZ8186 and AZ2014 were
supplied by Astra Zeneca under MTA/RCA with the CRUK Beatson Institute.
Drugs were dissolved and administered in 0.5% HPMC, 0.1% Tween 20, H2O
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vehicle. Endpoint monitoring was performed by CRUK Beatson Institute Biological
Services facility staff without knowledge of genotype.
For histological analysis, mouse tissues were fixed with 10% neutral
buffered formalin overnight. All immunohistochemistry was performed as
described78 on 4 µm formalin-fixed paraffin-embedded sections which had
previously been heated to 60 °C for 2 h. Peroxidase blocking was performed for
10 mins in 1% H2O2 diluted in H2O, followed by heat-mediated antigen
retrieval. Non-specific antibody binding was blocked with 3% BSA or 5%
normal goat serum for 1 h at RT. The following antibodies were used at the
indicated dilution and indicated antigen retrieval method: phospho-S6 (Cell
Signaling Tech. 5634, 1;1000), ER2 antigen retrieval solution (Leica). Anti-
rabbit Ig (Vector Labs) was used as the secondary antibody. The HRP signal
was detected using liquid DAB (Invitrogen). Sections were counterstained with
haematoxylin and cover-slipped using DPX mount (Cellpath, UK).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The polysome data generated in this study have been deposited in https://www.ebi.ac.uk/
arrayexpress/experiments with accession code E-MTAB-8167 [ArrayExpress - E-MTAB-
6351]. The processed data from this study of the mRNAs whose polysome association
changes can be found in the excel spreadsheets in Supplementary data 1 and the GO
analysis is present in Supplementary data 2. The raw patient data collected under NHS
ethics agreement 14/EM/1159 are protected and are not available owing to data privacy
laws. However, anonymised raw patient data are available upon application to Professor
John Le Quesne (Professor in Molecular Pathology Institute of Cancer Sciences, John.
LeQuesne@glasgow.ac.uk). The metabolite data used to generate Figs. 4 and 6 are
available as excel spreadsheets in Supplementary data 3 and 4. Raw metabolomics data
are available upon request to Dr. David Sumpton (Head of Metabolomics, Beatson
Institute for Cancer Research, UK) via email (d.sumpton@beatson.gla.ac.uk). Source data
are provided with this paper.
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